Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries

Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon

Eugia Pharma receives USFDA Approval for Icatibant Injection

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities

SSI Strategy to acquires NDA Group partner to form global life sciences consultancy

Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.

Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma

ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity

Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression

Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA

Gujarat Themis Biosyn posts Q1 FY24 PAT at Rs. 17.72 Cr

Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023

Abbott India's Q1 FY24 PAT up at Rs. 290.24 Cr

Abbott India has reported total income of Rs. 1535 crores during the period ended June 30, 2023